This cohort study estimates changes in the rate of respiratory syncytial virus (RSV)–associated hospitalizations and emergency department visits among infants during the first 2 respiratory seasons during which nirsevimab and antenatal RSV vaccine were available.
JAMA Network Open published a clinical update in Research Highlights on 08 Apr 2026.
The item focuses on RSV Prevention Products and Severe RSV-Associated Disease Among Infants.
Review the original article for the full source wording and details.